- Home
- GRX vs AARD Comparison
GRX vs AARD Comparison
Compare GRX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- AARD
- Stock Information
- Founded
- GRX 2007
- AARD 2017
- Country
- GRX United States
- AARD United States
- Employees
- GRX N/A
- AARD N/A
- Industry
- GRX Finance/Investors Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- AARD Health Care
- Exchange
- GRX Nasdaq
- AARD Nasdaq
- Market Cap
- GRX 148.5M
- AARD 154.9M
- IPO Year
- GRX N/A
- AARD 2025
- Fundamental
- Price
- GRX $9.31
- AARD $11.13
- Analyst Decision
- GRX
- AARD Strong Buy
- Analyst Count
- GRX 0
- AARD 4
- Target Price
- GRX N/A
- AARD $31.25
- AVG Volume (30 Days)
- GRX 39.7K
- AARD 29.5K
- Earning Date
- GRX 01-01-0001
- AARD 08-14-2025
- Dividend Yield
- GRX 5.98%
- AARD N/A
- EPS Growth
- GRX N/A
- AARD N/A
- EPS
- GRX 0.26
- AARD N/A
- Revenue
- GRX N/A
- AARD N/A
- Revenue This Year
- GRX N/A
- AARD N/A
- Revenue Next Year
- GRX N/A
- AARD N/A
- P/E Ratio
- GRX $38.50
- AARD N/A
- Revenue Growth
- GRX N/A
- AARD N/A
- 52 Week Low
- GRX $7.73
- AARD $4.88
- 52 Week High
- GRX $10.40
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- GRX 38.70
- AARD N/A
- Support Level
- GRX $9.26
- AARD N/A
- Resistance Level
- GRX $9.74
- AARD N/A
- Average True Range (ATR)
- GRX 0.10
- AARD 0.00
- MACD
- GRX -0.03
- AARD 0.00
- Stochastic Oscillator
- GRX 10.42
- AARD 0.00
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.